BioAlliance Pharma and Topotarget Agree to Merge and Combine Late-State Orphan Oncology Assets
By Heather Cartwright
Pharma Deals Review: Vol 2014 Issue 5 (Table of Contents)
Published: 16 May-2014
DOI: 10.3833/pdr.v2014.i5.2027 ISSN: 1756-7874
Section: Mergers & Acquisitions
Fulltext:
Abstract
In a deal aimed at creating scale, France’s BioAlliance Pharma and Denmark’s Topotarget have agreed to combine their orphan oncology assets via a merger agreement...
This page is available to subscribers only.
Not a subscriber? Join here
Already Registered? Please login using the top left purple box.
Copyright: © IQVIA 2018
RSS